title: Pharmacogenomics and pancreatic cancer treatment. Optimizing current therapy and individualizing future therapy.
abstract: Each year, more than 30,000 Americans are diagnosed with pancreatic cancer. We have only made incremental advancements in treatment of pancreatic cancer despite our best efforts. Research has revealed that pancreatic cancer is a genetic disease which is associated with various forms of cancer associated genetic alterations. Identification and understanding of these carcinogenic gene alterations is the base upon which we can overcome drug resistance and develop novel treatment approaches. In this paper, we review current understanding of pharmacogenomics of pancreatic cancer treatment and address future direction of the field.
authors.forename: Soonmo Peter
authors.initials: SP
authors.lastname: Kang
authors.forename: Muhammad Wasif
authors.initials: MW
authors.lastname: Saif
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D003603:Cytotoxins / Q000627:therapeutic use; D016503:Drug Delivery Systems; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005544:Forecasting; D006801:Humans; D007206:Individuality; D009154:Mutation; D010190:Pancreatic Neoplasms / Q000235:genetics* / Q000628:therapy*; D010597:Pharmacogenetics; D017671:Platinum Compounds / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D003603:Cytotoxins; D017671:Platinum Compounds; D011743:Pyrimidines